收稿日期: 2022-08-29
录用日期: 2022-09-07
网络出版日期: 2022-09-23
基金资助
上海市临床重点专科建设项目
New progress and prospects of blood glucose monitoring technology
Received date: 2022-08-29
Accepted date: 2022-09-07
Online published: 2022-09-23
Supported by
Shanghai Municipal Key Clinical Specialty
血糖监测是糖尿病综合管理的重要组成部分。近1个多世纪以来,糖尿病监测技术由最初的尿糖检测,到后来的血糖检测,再到目前的持续葡萄糖监测(continuous glucose monitoring,CGM),不断向便捷、准确、微创,甚至无创的方向发展。近年来不断发展的CGM技术,可连续、动态地监测全天人体组织间液葡萄糖浓度的变化,发现不易被传统血糖监测方法探测到的隐匿性高血糖和低血糖。利用CGM技术提供的海量血糖信息,有望使糖尿病管理方案的制定更具针对性,真正做到精准控糖。而与之相应的,以葡萄糖目标范围内时间(time in range,TIR)为代表的血糖控制新指标备受关注,能更全面地提供包括高血糖、低血糖以及血糖波动等信息,与传统血糖指标糖化血红蛋白等互为补充。未来,应进一步研发舒适、稳定、准确性高的成熟、微创甚至无创血糖监测技术,以大幅提高患者血糖监测的体验感和积极性;同时,积极推动闭环胰岛素输注系统研发,真正实现个体化、自动化血糖控制,以进一步提高糖尿病患者的血糖控制水平。
关键词: 糖尿病; 持续葡萄糖监测; 葡萄糖目标范围内时间
贾伟平 . 血糖监测技术的进步与展望[J]. 上海交通大学学报(医学版), 2022 , 42(9) : 1171 -1175 . DOI: 10.3969/j.issn.1674-8115.2022.09.002
Glucose monitoring is an important part of diabetes management. For over a century, diabetes monitoring technology has developed from the initial urine glucose test, to the later blood glucose test, and finally to the current continuous glucose monitoring (CGM), which is evolving in a more convenient, accurate, minimally invasive, and even non-invasive direction. CGM refers to the technology that continuously measures glucose concentrations in the subcutaneous interstitial fluid by glucose sensors. It can detect hyperglycemia and hypoglycemia that are not easily recognized by traditional monitoring methods. Using the huge amounts of glucose data generated by CGM technology, diabetes management is expected to be more targeted, with glucose control more accurate. In this context, novel measure of glucose control represented by time in range (TIR) has been popularized, which can provide comprehensive information including hyperglycemia, hypoglycemia, and glucose fluctuation. Hence, the modern approach to glucose control should focus not only on glycosylated hemoglobin, but also pay attention to new metrics such as TIR. In the future, more mature, minimally invasive and even non-invasive glucose monitoring technologies that are comfortable, stable and highly accurate should be further developed to greatly improve the experience and enthusiasm of the patients in blood glucose monitoring. Meanwhile, closed-loop insulin infusion system should be further developed, to truly realize individualized and automated glucose control, as well as further improvement of glucose control in the patients with diabetes.
1 | International Diabetes Federation. IDF diabetes atlas 2021[M]. 10th ed. Brussels: International Diabetes Federation, 2021. |
2 | LI H Q, TIAN S H, CHEN T, et al. Newly diagnosed diabetes is associated with a higher risk of mortality than known diabetes in hospitalized patients with COVID-19[J]. Diabetes Obes Metab, 2020, 22(10): 1897-1906. |
3 | RAHBAR S. An abnormal hemoglobin in red cells of diabetics[J]. Clin Chimica Acta, 1968, 22(2): 296-298. |
4 | SELVIN E. Hemoglobin A1c—using epidemiology to guide medical practice: Kelly West Award Lecture 2020[J]. Diabetes Care, 2021, 44(10): 2197-2204. |
5 | 戴冬君, 周健. 组织间液葡萄糖监测的意义及研究进展[J]. 中华医学杂志, 2018, 98(40): 3296-3298. |
5 | DAI D J, ZHOU J. Significance and research progress of interstitial fluid glucose monitoring[J]. Natl Med J China, 2018, 98(40): 3296-3298. |
6 | CLARK L C Jr, LYONS C. Electrode systems for continuous monitoring in cardiovascular surgery[J]. Ann N Y Acad Sci, 1962, 102(1): 29-45. |
7 | 贾伟平. 持续葡萄糖监测[M]. 上海: 上海科学技术出版社, 2017. |
7 | JIA W P. Contiuous glucose monitoring[M]. Shanghai: Shanghai Scientific & Technical Publishers, 2017. |
8 | EHRHARDT N, HIRSCH I B. The impact of COVID-19 on CGM use in the hospital[J]. Diabetes Care, 2020, 43(11): 2628-2630. |
9 | SHEN Y, FAN X H, ZHANG L, et al. Thresholds of glycemia and the outcomes of COVID-19 complicated with diabetes: a retrospective exploratory study using continuous glucose monitoring[J]. Diabetes Care, 2021, 44(4): 976-982. |
10 | 中华医学会糖尿病学分会. 中国血糖监测临床应用指南(2021年版)[J]. 中华糖尿病杂志, 2021, 13(10): 936-948. |
10 | Chinese Diabetes Society. Clinical application guideline for blood glucose monitoring in China (2021 edition)[J]. Chin J Diabetes Mellitus, 2021, 13(10): 936-948. |
11 | LU J Y, WANG C F, CAI J H, et al. Association of HbA1c with all-cause mortality across varying degrees of glycemic variability in type 2 diabetes[J]. J Clin Endocrinol Metab, 2021, 106(11): 3160-3167. |
12 | DANNE T, NIMRI R, BATTELINO T, et al. International consensus on use of continuous glucose monitoring[J]. Diabetes Care, 2017, 40(12): 1631-1640. |
13 | LU J Y, MA X J, ZHANG L, et al. Glycemic variability modifies the relationship between time in range and hemoglobin A1c estimated from continuous glucose monitoring: a preliminary study[J]. Diabetes Res Clin Pract, 2020, 161: 108032. |
14 | 戴冬君, 陆静毅, 周健. 持续葡萄糖监测新指标: 葡萄糖在目标范围内时间的临床意义解析[J]. 中华糖尿病杂志, 2019, 11(2): 139-142. |
14 | DAI D J, LU J Y, ZHOU J. A new indicator of continuous glucose monitoring: analysis of the clinical significance of time in range[J]. Chin J Diabetes Mellitus, 2019, 11(2): 139-142. |
15 | LU J Y, MA X J, ZHOU J, et al. Association of time in range, as assessed by continuous glucose monitoring, with diabetic retinopathy in type 2 diabetes[J]. Diabetes Care, 2018, 41(11): 2370-2376. |
16 | BECK R W, BERGENSTAL R M, RIDDLESWORTH T D, et al. Validation of time in range as an outcome measure for diabetes clinical trials[J]. Diabetes Care, 2019, 42(3): 400-405. |
17 | LU J Y, WANG C F, SHEN Y, et al. Time in range in relation to all-cause and cardiovascular mortality in patients with type 2 diabetes: a prospective cohort study[J]. Diabetes Care, 2021, 44(2): 549-555. |
18 | MAYEDA L, KATZ R, AHMAD I, et al. Glucose time in range and peripheral neuropathy in type 2 diabetes mellitus and chronic kidney disease[J]. BMJ Open Diabetes Res Care, 2020, 8(1): e000991. |
19 | YOO J H, CHOI M S, AHN J, et al. Association between continuous glucose monitoring-derived time in range, other core metrics, and albuminuria in type 2 diabetes[J]. Diabetes Technol Ther, 2020, 22(10): 768-776. |
20 | GUO Q Y, ZANG P, XU S Y, et al. Time in range, as a novel metric of glycemic control, is reversely associated with presence of diabetic cardiovascular autonomic neuropathy independent of HbA1c in Chinese type 2 diabetes[J]. J Diabetes Res, 2020, 2020: 5817074. |
21 | KIM M Y, KIM G, PARK J Y, et al. The association between continuous glucose monitoring-derived metrics and cardiovascular autonomic neuropathy in outpatients with type 2 diabetes[J]. Diabetes Technol Ther, 2021, 23(6): 434-442. |
22 | LU J Y, MA X J, SHEN Y, et al. Time in range is associated with carotid intima-media thickness in type 2 diabetes[J]. Diabetes Technol Ther, 2020, 22(2): 72-78. |
23 | XIE P G, DENG B, ZHANG X, et al. Time in range in relation to amputation and all-cause mortality in hospitalised patients with diabetic foot ulcers[J]. Diabetes Metab Res Rev, 2022, 38(2): e3498. |
24 | KRISTENSEN K, ?GGE L E, SENGPIEL V, et al. Continuous glucose monitoring in pregnant women with type 1 diabetes: an observational cohort study of 186 pregnancies[J]. Diabetologia, 2019, 62(7): 1143-1153. |
25 | ZHENG Y W, SHEN Y, JIANG S S, et al. Maternal glycemic parameters and adverse pregnancy outcomes among high-risk pregnant women[J]. BMJ Open Diabetes Res Care, 2019, 7(1): e000774. |
26 | American Diabetes Association. 6. Glycemic targets: standards of medical care in diabetes—2021[J]. Diabetes Care, 2021, 44(Suppl 1): S73-S84. |
27 | GRUNBERGER G, SHERR J, ALLENDE M, et al. American Association of Clinical Endocrinology clinical practice guideline: the use of advanced technology in the management of persons with diabetes mellitus[J]. Endocr Pract, 2021, 27(6): 505-537. |
28 | WILMOT E G, LUMB A, HAMMOND P, et al. Time in range: a best practice guide for UK diabetes healthcare professionals in the context of the COVID-19 global pandemic[J]. Diabet Med, 2021, 38(1): e14433. |
29 | BATTELINO T, DANNE T, BERGENSTAL R M, et al. Clinical targets for continuous glucose monitoring data interpretation: recommendations from the international consensus on time in range[J]. Diabetes Care, 2019, 42(8): 1593-1603. |
/
〈 |
|
〉 |